Novo Nordisk’s diabetes drug Ozempic again in provide in US after months of scarcity

(Reuters) -Novo Nordisk’s best-selling diabetes therapy drug Ozempic is again on the cabinets in the US after months of scarcity, the U.S. Meals and Drug Administration (FDA) web site confirmed on Friday.

The principle lively ingredient in Ozempic is semaglutide, additionally the important thing ingredient in Novo’s weight problems drug Wegovy, which has been seeing provide scarcity because of excessive demand.

The corporate stated the 0.25 mg, 0.5 mg and the 1 mg doses of Ozempic can be found for sufferers. The two mg dose, nevertheless, has restricted availability till the tip of this month, largely as a result of demand coupled with total world provide constraints.

“Whereas product continues to be manufactured and shipped, sufferers in some areas of the nation will expertise delays with the 2mg dose,” Novo Nordisk stated.

In February, the corporate had warned of provide constraints this 12 months on Ozempic. The drug recorded gross sales of 59.75 billion Danish crowns ($8.56 billion) in 2022.

Ozempic’s demand was additionally seen to be partly pushed by prescriptions to non-diabetic sufferers looking for to drop pounds, which is outdoors the drug’s authorised indication.

($1 = 6.9785 Danish crowns)

(Reporting by Khushi Mandowara and Raghav Mahobe in Bengaluru; Enhancing by Shailesh Kuber)